A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Inclusion Criteria: * Age ≥ 50 years at time of signing Informed Consent Form * Initial diagnosis of nAMD within 9 months prior to the screening visit * Previous treatment with at least three anti- vascular endothelial growth factor (VEGF) intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit * Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis * Availability of historical visual acuity data prior to the first anti-VEGF treatment for nAMD until the time of study enrollment * BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better Exclusion Criteria: * History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye * Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary thermotherapy in study eye * Previous treatment with corticosteroid intravitreal injection, intraocular device implantation, previous laser (any type) used for AMD treatment in study eye * Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the enrollment visit in study eye * Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant * Prior treatment with brolucizumab (at any time prior to the screening visit) in either eye * Prior participation in a clinical trial invo…